Approaches for the Development of Drugs for Treatment of Obesity and Metabolic Syndrome.

Autor: Maksimov ML; Department of Pharmacology of Pharmaceutical Faculty of I. M. Sechenov First Moscow State Medical University, Moscow, Russia (121019, Moscow, Nikitsky Blvd., 13). tchoubarov@mail.ru., Svistunov AA, Tarasov VV, Chubarev VN, Ávila-Rodriguez M, Barreto GE, Dralova OV, Aliev G

Publikováno v: Current pharmaceutical design [Curr Pharm Des] 2016; Vol. 22 (7), pp. 895-903.

[Correction of aldosterone level as marker of RAAS dysfunction in patients with arterial hypertension degree II-III and chronic kidney diseases].

Autor: Dralova OV, Maksimov ML, Derbentseva EA, Ermolaeva AS, Starodubtsev AK

Publikováno v: Eksperimental'naia i klinicheskaia farmakologiia [Eksp Klin Farmakol] 2011; Vol. 74 (4), pp. 14-7.

[Antihypertensive and nephroprotective effectiveness of AT1-angiotensin II receptor blocker valsartan in average therapeutic and maximal daily dose in patients with arterial hypertension and chronic kidney disease].

Autor: Maksimov MA, Derbentseva EA, Dralova OV, Starodubtsev AK, Ostroumova OD

Publikováno v: Kardiologiia [Kardiologiia] 2011; Vol. 51 (1), pp. 74-8.